2025年12月29日,Aptevo治疗技术公司完成了18对18的逆向股票分割,股份从1 800万减少到100万。 Aptevo Therapeutics completed a 1-for-18 reverse stock split on Dec. 29, 2025, reducing shares from 18 million to 1 million.

从2025年12月29日起,Aptevo治疗学公司(APVO)执行了一对一18逆向股分法,将未清股票从约1 800万减少到约100万。 Aptevo Therapeutics (APVO) executed a 1-for-18 reverse stock split effective December 29, 2025, reducing outstanding shares from about 18 million to roughly 1 million. 12月30日,按拆分调整办法恢复了交易,股票符号或面值不变。 Trading resumed on December 30 on a split-adjusted basis, with no change to the stock symbol or par value. 股东收到用于分股的现金。 Shareholders received cash for fractional shares. 这项动议于2025年7月得到股东批准,并于12月最后敲定,按比例调整了所有股权工具,但不影响授权的股票或资本结构。 The move, approved by shareholders in July 2025 and finalized in December, adjusts all equity instruments proportionally but does not affect authorized shares or capital structure. 该公司正在发展免疫-肿瘤治疗,继续推进癌症临床和临床前方案。 The company, developing immune-oncology therapies, continues advancing clinical and preclinical programs for cancer.